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Cross-resistance to five glucocorticoids in childhood acute
lymphoblastic and non-lymphoblastic leukemia samples tested
by the MTT assay: Preliminary report
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In vitro antileukemic activity of five glucocorticoids and their cross-resistance pat-
tern in childhood acute lymphoblastic and non-lymphoblastic leukemia were deter-
mined by means of the MTT assay in 25 leukemia cell samples of childhood acute
leukemias. The equivalent antileukemic concentrations of the drugs tested were:
34 M hydrocortisone (HC), 8 M prednisolone (PRE), 1.5 M methylprednisolone
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Abbreviations: ALL, acute lymphoblastic leukemia; iALL, initial ALL; rALL, relapsed ALL; AML, acute
myeloblastic leukemia; BET, betamethasone; BM, bone marrow; DX, dexamethasone; HC, hydrocorti-
sone; MPR, methylprednisolone; PB, peripheral blood; PRE, prednisolone; RR, relative resistance.(MPR), 0.44 M dexamethasone (DX) and 0.22 M betamethasone (BET). In compari-
son with initial ALL cell samples, the relapsed ALL group was more resistant to PRE
(38-fold, p = 0.044), DX (> 34-fold, p = 0.04), MPR (38-fold), BET (45-fold) and HC
(33-fold).TheAMLcellsampleswereevenmoreresistantto:PRE(>85-fold,p=0.001),
DX(>34-fold,p=0.004),MPR(>69-fold,p=0.036),BET(>69-fold,p=0.038)andHC
(54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant
cross-resistance among all the glucocorticoids used was found. Only in some individ-
ual cases the cross-resistance was less pronounced.
Glucocorticoids are important drugs in ther-
apy of acute lymphoblastic leukemia (ALL)
butresistancetothoseagentsisamajorobsta-
cle in the progress of anti-leukemic therapy.
On the other hand, this group of drugs is not
used in therapy of acute myeloblastic leuke-
mia (AML) due to clinical resistance of myelo-
blasts. Resistance in vitro and in vivo to
glucocorticoids is nowadays one of the stron-
gest adverse risk factors in the treatment of
childhood acute lymphoblastic leukemia
[1–2].Basedontheresultsobtainedbothwith
experimental cell lines and patients’ leukemic
cell samples, the most important resistance
mechanisms to glucocorticoids include: ab-
normalities in number, morphology and func-
tion of glucocorticoid receptors [3–4], upre-
gulation of transmembrane P-glycoprotein
[5], intracellular level of glutathione and its
S-transferases[6],changesinDNArepairpro-
cesses [7], heat shock proteins expression [8],
and apoptosis disregulation, especially in the
mitochondrial pathway [3]. Future clinical
possibilities to overcome the resistance to
glucocorticoids include the use either of resis-
tance modifiers or a drug with the highest
anti-leukemic activity for individual patient.
Possible modulation of resistance, including
administrationofamodifiertogetherwiththe
glucocorticoid, is still far from clinical prac-
tice.Ontheotherhand,theroleandtheuseof
prednisolone and dexamethasone in different
therapeutic protocols for childhood ALL is
not yet strictly established. Differential
cytotoxicity of those drugs against human
lymphoblasts has been reported in several
studies [9–11].
Theobjectiveofthestudywasthedetermina-
tion of antileukemic activity and cross-re-
sistance pattern among five various gluco-
corticoidsinsamplesofchildhoodacuteleuke-
mia. In addition to prednisolone and dexa-
methasone, the basic drugs in the therapy of
ALL, we tested three glucocorticoids which
are in common use in treatment of numerous
non-proliferative diseases, due to their anti-in-
flammatory properties: hydrocortisone,
methylprednisolone and betamethasone.
MATERIAL AND METHODS
Leukemic cells were from children with
acute lymphoblastic leukemia on diagnosis
(iALL, n = 13), rALL on relapse (n = 6) and
with acute non-lymphoblastic leukemia on di-
agnosis (iAML, n = 6). The analyzed group of
patients consisted of 17 boys and 8 girls, aged
0.6–18 yrs (median 9 yrs). Each patient was
included only once in the study.
In vitro drug resistance was established by
means of the MTT assay [12]. The following
glucocorticoids were tested: prednisolone
(PRE), dexamethasone (DX), betamethasone
(BET), methylprednisolone (MPR) and hy-
drocortisone (HC) (Table 1, Scheme 1). Drug
concentration lethal to 50% of tested cells
(LC50) was used as a measure of cytotoxicity.
Differences between groups were compared
with Mann-Whitney U test. Cross-resistance
betweenthecytotoxicityofeachpairofdrugs
was determined by Spearman’s rho coeffi-
cient of correlation. The study was approved
by the Local Ethics Committee, Medical Uni-
versity, Bydgoszcz.
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The equivalent antileukemic concentrations
of the drugs tested were: 34 M HC, 8 M
PRE, 1.5 M MPR, 0.44 M DX and 0.22 M
BET. In comparison with initial ALL samples,
the relapsed group of ALL was more resistant
to PRE (38-fold, p = 0.044), DX (> 34-fold,
p=0.04),MPR(38-fold),BET(45-fold)andHC
(33-fold).TheAMLgroupofpatientswaseven
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Table 1. Drugs and concentrations tested
Molecular mass Concentration range
[g/mol] [g/ml] [M]
Betamethasone 392.0 0.000183–6 0.5 nM–15.3
Dexamethasone 392.0 0.000183–6 0.5 nM–15.3
Methylprednisolone 374.4 0.0012207–40 3.2 nM–106.8
Prednisolone 360.0 0.007629–250 0.0212–694
Hydrocortisone 362.5 0.0244141–800 0.0673–2.2 mM
CORTISOL (HYDROCORTISONE) PREDNISONE
PREDNISOLONE METHYLPREDNISOLONE
DEXAMETHASONE BETAMETHASONE
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Scheme 1. Chemical structure of glucocorticoidsmore resistant to PRE (> 85-fold, p = 0.001),
DX (> 34-fold, p = 0.004), MPR (> 69-fold,
p = 0.036), BET (> 69-fold, p = 0.038) and HC
(54-fold, p = 0.059) compared with the ALL on
initial diagnosis group (Table 2). A significant
cross-resistance between all glucocorticoids
used was observed (Table 3). In some individ-
ual cases the cross-resistance was less pro-
nounced.
A significant correlation was observed be-
tweenthecytotoxicitiesofstructurallysimilar
drugs, such as DX and BET (Table 3). In 3/6
AML cases maximum resistance to all five
glucocorticoids was observed; in all other
cases, except one, the LC50 values were not
lower than 1/2 of the highest concentration
tested. In 5/6 AML cases maximum resis-
tance to PRE and DX was seen. In four cases,
even a stimulation by at least one gluco-
corticoid of myeloblast growth was observed.
In one case, however, good sensitivity to BET
was observed.
DISCUSSION
Resistance to glucocorticoids can play a role
in pathogenesis of various diseases, such as
autoimmunologic disorders, AIDS, Nelson
syndrome, sclerosis multiplex and leukemias
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Table 2. Median cytotoxicity (LC50) and relative resistance to glucocorticoids
LC50 [M] Relative resistance (RR)
iALL rALL iAML RR(rALL vs iALL)* RR (iAML vs iALL)**
Betamethasone 0.22 9.8 > 15.3 44.8; p = 0.072 > 69; p = 0.038
Dexamethasone 0.44 > 15.3 > 15.3 >34.2; p = 0.040 > 34.2; p = 0.004
Methylprednisolone 1.55 59.5 > 106.8 38.4; p = 0.15 > 69; p = 0.036
Prednisolone 8.1 308.3 > 694 38.0; p = 0.044 > 85; p = 0.001
Hydrocortisone 34.7 1155 1894 33.0; p = 0.13 54; p = 0.059
RR, relative resistance in comparison with iALL; (*) RR is the median LC50 for rALL divided by the median LC50 for iALL;
(**) RR is the median LC50 for iAML divided by the median LC50 for iALL; RR >1 indicates that for the given drug, rALL
(iAML) is more resistant than iALL; p, Mann-Whitney U test.
Table 3. Correlation matrix of glucocorticoids cross-resistance
PRE DX BET MPR HC
PRE 0.625 0.550 0.407 0.525
0.001 0.008 0.043 0.007
DX 0.625 0.681 0.352 0.639
0.001 < 0.001 0.084 0.001
BET 0.550 0.681 0.461 0.690
0.008 <0.001 0.031 < 0.001
MPR 0.407 0.352 0.461 0.693
0.043 0.084 0.031 < 0.001
HC 0.525 0.639 0.690 0.693
0.007 0.001 < 0.001 <0.001
Upper value in each area is the value of Spearman’s rho coefficient of correlation of LC50 values for a pair of drugs, lower
value – p, value of this coefficient. PRE, prednisolone; DX, dexamethasone; BET, betamethasone; MPR, methylprednisolone;
HC, hydrocortisone.[13]. Recent studies demonstrate that pri-
mary (hereditary) abnormalities in the
glucocorticoid receptor gene make 6.6% of the
normal population relatively ‘hypersensitive’
to glucocorticoids, while 2.3% are relatively
“resistant”. These abnormalities might ex-
plain the well-known phenomenon that some
individuals develop severe adverse effects
during therapy with a low dose of gluco-
corticosteroids, while others do not develop
side effects even during long-term therapy
with a much higher dose [14]. In childhood
ALL in vitro glucocorticoid resistance is ob-
served in 41–48% patients on diagnosis. After
repeated cycles of chemotherapy including
glucocorticoids, the rate of glucocorticoid re-
sistance reaches 60–90% patients at relapse
[1, 15]. The sensitivity to glucocorticoids is
thought to be one of the most important prog-
nosticfactorsinvarioustherapeuticprotocols
for children with ALL. Prednisolone resis-
tance is thought to be the strongest single ad-
verse prognostic factor [1–2, 9–11, 15].
Glucocorticoids are the most important
cytotoxic drugs in the therapy of ALL. Recent
studies have shown that the response of ALL
to glucocorticoid therapy increases with drug
dose. High-dose corticosteroid treatment ab-
rogatestheeffectofrelativedruginsensitivity
and of low glucocorticoid receptor number on
peripheral blasts [16].
In our study, based solely on clinical mate-
rial, we determined in vitro cross-resistance
pattern between prednisolone, dexametha-
sone, betamethasone, methylprednisolone
and hydrocortisone in samples from child-
hood acute leukemia. We showed that
betamethasone, methylprednisolone and hy-
drocortisone cannot circumvent resistance to
prednisolone and dexamethasone in child-
hood ALL and even showed worse activity
against AML, with a possible exception of
betamethasone. We observed that each of the
glucocorticoids tested could stimulate in vitro
proliferation of myeloblasts in 4-day culture,
similar to the results of another study [17].
We noticed, however, that in individual pa-
tients cells could be identified as sensitive to
betamethasone but resistant to prednisolone
or dexamethasone. An additional observation
of the present study is that DX has a 17-fold
higher antileukemic potency than PRE, which
was suggested earlier [10]. The activity of
BET against leukemic cells was found to be
2-fold higher than that of DX. These results
suggest that antileukemic properties of the
glucocorticoids tested may differ from their
anti-inflammatory activity, as DX is usually
thought to be 7-fold more active than PRE,
and BET about 1.5-fold more active than DX.
In conclusion, the results of the study suggest
that a subgroup of patients with leukemia can
berecognized,forwhomtheindividualprofile
of cytotoxicity to glucocorticoids can help to
choose the drug with the highest antileukemic
potency and possibly more favourable
pharmacokinetics.
Authors thank Beata Ko³odziej for technical
assistance.
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